Background: Refractory epilepsy is a significant problem in clinical practice. Sometimes, multiple antiepileptic drugs are required to control the attacks. To avoid various complications ensuring from these drugs, new methods of treatment such as vagus nerve stimulation (VNS) have been recommended. Trigeminal nerve stimulation (TNS) is a new method under evaluation. The purpose of this paper is to determine whether this method is effective or not.
Materials and Methods: Percutaneous simulation of supraorbital branches of the trigeminal nerve by an electrical device was planned in 18 patients over a six-month period. Participants who fulfilled the research criteria were selected randomly from epileptic patients referred to the clinic. (November 2011-December 2012). T-test was used for data analysis.
Results: Only eight of 18 patients stayed in the study during all 6 months. A 47.9% reduction in daily seizure frequency was seen in this group (P = 0.022). Other subjects left the study earlier. In this group, seizure frequency increased by 10.6% (P = 0.82).
Conclusions: The mechanism of the antiepileptic effects of TNS is not yet clear. In animal studies, it is suggested that the trigeminal nucleus and its projection to nucleus tractus solitarius (NTS) and the locus ceruleus, are involved in seizure modulation.Although in comparison with seizure frequency prior to the study there was significant seizure reduction, according to the usual criteria for VNS i.e. 50% seizure frequency reduction, the effect of TNS per se may not yet be adequate for treatment of seizures. Trigeminal nerve stimulation may be an effective "adjuvant" method for treatment of intractable seizure.
|1.||Begley CE, Famulari M, Annegers JF, Lairson DR, Reynolds TF, Coan S, et al. The cost of epilepsy in United States: An estimate from population- Based clinical and survey data. Epilepsia 2000;41:342-51.
|2.||DeGiorgio CM, Fanselow EE, Schrader LM, Cook IA.Trigeminal nerve stimulation: Seminal animal and human study for epilepsy and depression. NeurosurgClin N Am 2011;22:449-56.
|3.||Najafi MR, Saadatnia M, Saffarifard A, Keyhanian K, Davoudi V. Epidemiology of restless legs syndrome in the Iranian population. Sleep Biol Rhythms 2011;9:56-9.
|4.||Ramsay RE, Uthman BM, Augustinsson LE, Upton AR, Naritoku D, Willis J, et al. Vagus nerve stimulation for treatment of partial seizures: Safety, side effects, and tolerability. First International Vagus Nerve stimulation study group. Epilepsia 1994;35:627-36.
|5.||DeGiorgio CM, Shewmon A, Murray D, Whitehurst T. Pilot study of trigeminal nerve stimulation for epilepsy: A proof- of- concept trial. Epilepsia 2006;47:1213-5.
|6.||Krahl SE, Clark KB, Smith DC, Browning RA. locus ceruleus lesions suppress the seizure- attenuating effects of vagus nerve stimulation. Epilepsia 1998;39:709-14.
|7.||Raedt R, Clinckers R, Mollet L, Vonck K, El Tahry R, Wyckhuys T, et al. Increased hyppocampal noradrenalin is a biomarker for efficacy of vagus nerve stimulation in a limbic seizure model. J Neurochem 2011;117:461-9.
|8.||Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: A meta-analytic approach. Epilepsia 2010;51:883-90.
|9.||French JA. Refractory epilepsy: Clinical overview. Epilepsia 2007;48(Suppl1):3-7.|